Literature DB >> 15980367

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Ralf René Reinert1, Susanne Reinert, Mark van der Linden, Murat Y Cil, Adnan Al-Lahham, Peter Appelbaum.   

Abstract

Susceptibility testing results for Streptococcus pneumoniae isolates (n = 2,279) from eight European countries, examined in the PneumoWorld Study from 2001 to 2003, are presented. Overall, 24.6% of S. pneumoniae isolates were nonsusceptible to penicillin G and 28.0% were resistant to macrolides. The prevalence of resistance varied widely between European countries, with the highest rates of penicillin G and macrolide resistance reported from Spain and France. Serotype 14 was the leading serotype among penicillin G- and macrolide-resistant S. pneumoniae isolates. One strain (PW 158) showed a combination of an efflux type of resistance with a 23S rRNA mutation (A2061G, pneumococcal numbering; A2059G, Escherichia coli numbering). Six strains which showed negative results for mef(A) and erm(B) in repeated PCR assays had mutations in 23S rRNA or alterations in the L4 ribosomal protein (two strains). Fluoroquinolone resistance rates (levofloxacin MIC > or = 4 microg/ml) were low (Austria, 0%; Belgium, 0.7%; France, 0.9%; Germany, 0.4%; Italy, 1.3%; Portugal, 1.2%; Spain, 1.0%; and Switzerland, 0%). Analysis of quinolone resistance-determining regions showed eight strains with a Ser81 alteration in gyrA; 13 of 18 strains showed a Ser79 alteration in parC. The clonal profile, as analyzed by multilocus sequence typing (MLST), showed that the 18 fluoroquinolone-resistant strains were genetically heterogeneous. Seven of the 18 strains belonged to new sequence types not hitherto described in the MLST database. Europe-wide surveillance for monitoring of the further spread of these antibiotic-resistant S. pneumoniae clones is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980367      PMCID: PMC1168634          DOI: 10.1128/AAC.49.7.2903-2913.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.

Authors:  G C Schito; E A Debbia; A Marchese
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

3.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998.

Authors:  A C Fluit; M E Jones; F J Schmitz; J Acar; R Gupta; J Verhoef
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

8.  Optochin revisited: defining the optimal type of blood agar for presumptive identification of Streptococcus pneumoniae.

Authors:  M A Gardam; M A Miller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

9.  mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.

Authors:  A Tait-Kamradt; J Clancy; M Cronan; F Dib-Hajj; L Wondrack; W Yuan; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

10.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more
  30 in total

Review 1.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

2.  Molecular characterization of non-penicillin-susceptible Streptococcus pneumoniae in Norway.

Authors:  Maren K R Sogstad; E Arne Høiby; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

3.  Emergence of a unique multiply-antibiotic-resistant Streptococcus pneumoniae serotype 7B clone in Dhaka, Bangladesh.

Authors:  Mahbubur Rahman; Shahadat Hossain; Shereen Shoma; Harunur Rashid; Abdullah Hel Baqui; Mark van der Linden; Adnan Al-Lahham; Ralf René Reinert
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

4.  Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.

Authors:  Margaret Ip; Shirley S L Chau; Fang Chi; Amy Qi; Raymond W M Lai
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Streptococcus pneumoniae choline-binding protein E interaction with plasminogen/plasmin stimulates migration across the extracellular matrix.

Authors:  Cécile Attali; Cécile Frolet; Claire Durmort; Julien Offant; Thierry Vernet; Anne Marie Di Guilmi
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

6.  Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.

Authors:  Moses L Joloba; Benson R Kidenya; David P Kateete; Fred A Katabazi; Julian K Muwanguzi; Benon B Asiimwe; Simon P Alarakol; Jessica L Nakavuma; Saralee Bajaksouzian; Anne Windau; Michael R Jacobs
Journal:  Int J Antimicrob Agents       Date:  2010-05-15       Impact factor: 5.283

Review 7.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Reporting Emerging Resistance of Streptococcus pneumoniae from India.

Authors:  Kiran Chawla; Bimala Gurung; Chiranjay Mukhopadhyay; Indira Bairy
Journal:  J Glob Infect Dis       Date:  2010-01

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.